The obesity drugs waiting to hit the market Premium

Novo, Eli Lilly and Pfizer are among the dozens of drugmakers chasing an up to $100 billion market of obesity treatments, which could also include oral options in the future.

Novo Nordisk said a large study had shown its highly effective obesity drug Wegovy also had a clear cardiovascular benefit, boosting the Danish drugmaker’s hopes of moving beyond Wegovy’s image as a lifestyle drug.

Novo, Eli Lilly and Pfizer are among the dozens of drugmakers chasing an up to $100 billion market of obesity treatments, which could also include oral options in the future.

The following is a list of companies targeting the next big blockbuster opportunity:

Novo Nordisk said a large study had shown its highly effective obesity drug, Wegovy, also had a clear cardiovascular benefit

In June, the drugmaker reported late-stage trial data from a high-dose oral version of its drug, semaglutide, helping overweight or obese adults lose 15% of their body weight, in line with recent results for other experimental pills.

The company also has an older product, Saxenda, approved in 2014, but Wegovy is considered safer and more effective.

Eli Lilly reported last year that diabetes drug Mounjaro showed a 22.5% weight loss in people who were obese or overweight but did not have diabetes. Mounjaro is awaiting U.S. regulatory approval for the treatment of obesity.